A16AX06 - Miglustat |
Propably not porphyrinogenic |
PNP |
Rationale
Miglustat is water soluble and 70-80% of the dose is excreted unchanged in urine. It is not a substrate, inhibitor, or inducer of CYP enzymes.
Risk for gastrointestinal adverse events in the form of nausea, vomiting, diarrhoea, loss of weight and reduced appetite motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Butyl hydroxymethyl piperidine
Therapeutic characteristics
Miglustat is indicated for the treatment of adult patients with type 1 Gaucher disease and Niemann-Pick type C disease.
Very common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, vomiting, abdominal pain, diarrhoea, obstipation, loss of weight, reduced appetite, depression, insomnia, peripheral neuropathy, paraesthesia and impaired nerve conduction.
Metabolism and pharmakokinetics
Miglustat is not bound to plasma proteins. It is water soluble (Maegawa 2009 and McCormack 2003) and about 70-80% of the dose is excreted unchanged in urine. About 5 % of the dose is excreted as glucuronide. The elimination half-life is 6-7 hours.
No drug-drug interactions are observed (DRUID and Interaktionsdatabasen), which indicates that miglustat is not a substrate, inhibitor or inducer of CYP enzymes.
References
- Scientific articles
- Maegawa GH, van Giersbergen PL, et al. Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis. Mol Genet Metab. 2009 Aug;97(4):284-91. PMID 19447653. #4365
- McCormack PL, Goa KL. Miglustat. Drugs. 2003;63(22):2427-34. PMID 14609352. #1149
- Drug interaction databases
- DRUID miglustat #1146
- Interaktionsdatabasen miglustat #1147
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (miglustat) (Last edition: 02.2013). #1150
Similar drugs
© NAPOS 2024